2007•Leukemia ResearchRequires access

Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients

Wenli Zheng, Guangsen Zhang, Yunxiao Xu, Jian-kai Shen, Chong-Wen Dai, Min-Fei Pei

Open publisher page 15 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Arsenic trioxide, Thalidomide, Medicine, Myelodysplastic syndromes, Combination therapy, Internal medicine, Gastroenterology, Pharmacology

Back to paper search Browse research topics Original source

Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients — Research Paper | ScholarLens